1. Honing SF: Treatment of metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1996, pp. 669–734
2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion doxorubicin in Cooper type regimens. Br J Cancer 67: 801–805, 1993
3. Brambilla C, Rossi A, Bonfante V, et al.: Phase II study of Doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261–266, 1986
4. Hayat M, Chauvergne J, Fargeot P, et al.: Phase III chemotherapy comparing FAC versus FEC in advanced breast cancer: Preliminary results. Proc Am Assoc Clin Oncol C-460, 1984
5. Intini C, Zingali G, de Micheli P, et al.: FEC versus FAC in Advanced Breast Cancer. Results of an Italian Cooperative study. Cancer Chemother Pharmacol suppl 1 to vol 18: A38, 149, 1986